Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry

•Dual-antiplatelet therapy (DAPT) ≥1 year post myocardial infarction reduces major adverse cardiovascular events but increases bleeding.•Appropriate patient selection for DAPT ≥1 year post myocardial infarction is important to avoid undue bleeding complications.•In contemporary practice, DAPT use ≥1 year post myocardial infarction is prevalent and associated with patient and index event characteristics.•There are marked geographical variations in DAPT use ≥1 year post myocardial infarction.•Further clinical initiatives are needed to optimize patient selection for DAPT ≥1 year post myocardial infarction.